Related Experiment Video
Updated: Aug 30, 2026
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Preclinical safety profile of plasma prepared using the INTERCEPT Blood System
V Ciaravino1, T McCullough, G Cimino
1Cerus Corporation, Concord, California 94520, USA.
Background And Objectives:
The newly developed INTERCEPT Blood System for plasma uses the addition of a new psoralen, amotosalen HCl (AMOTOSALEN), followed by illumination with ultraviolet A light, to inactivate viruses, bacteria, protozoa and leucocytes that may contaminate fresh-frozen plasma (FFP). Extensive toxicology studies were performed to characterize the safety of the photochemical treatment process for its intended use with plasma.
Materials And Methods:
The studies of general toxicology, safety pharmacology, phototoxicity, reproductive toxicity and venous irritation, summarized in this review, provide a comprehensive toxicology profile for photochemically treated 100% plasma.
Results:
No specific target organ toxicity (based on clinical or histological pathology), phototoxicity, or reproductive toxicity was observed.
Conclusions:
The results of an extensive series of studies have demonstrated no toxicologically relevant effects of photochemically treated 100% plasma prepared using the INTERCEPT Blood System for plasma.
